Drug:
Reaction: MALIGNANT NEOPLASM PROGRESSION
20250101 - 20251231
No. 1001 - 1100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1001 | 24934053 |
US |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1002 | 24934055 |
FR |
53 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, PEMBROLIZUMAB, MORPHINE SULFATE, |
||||
| 1003 | 24934058 |
US |
1 | |
Malignant neoplasm progression, Drug ineffective, |
||||
CABOZANTINIB, |
||||
| 1004 | 24934062 |
RO |
40 | 2 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1005 | 24934065 |
SA |
56 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, NIVOLUMAB, |
||||
| 1006 | 24934068 |
PL |
2 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1007 | 24934072 |
NO |
51 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, NIVOLUMAB, |
||||
| 1008 | 24934076 |
US |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, CABOZANTINIB, |
||||
| 1009 | 24934077 |
US |
64 | 1 |
Osteonecrosis of jaw, Malignant neoplasm progression, Taste disorder, Diarrhoea, Vomiting, Weight decreased, Dyspnoea, Off label use, |
||||
CABOZANTINIB, ALPRAZOLAM, ESCITALOPRAM, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, OXYCODONE HYDROCHLORIDE, |
||||
| 1010 | 24934078 |
US |
1 | |
Malignant neoplasm progression, Off label use, |
||||
CABOZANTINIB, CABOZANTINIB, ONDANSETRON HYDROCHLORIDE, POLYETHYLENE GLYCOL 3350, DOCUSATE SODIUM, DOCUSATE SODIUM 100MG, ESCITALOPRAM OXALATE, ESCITALOPRAM, RIVAROXABAN, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, SULFAMETHOXAZOLE AND TRIMETHOPRIM, METHADONE HYDROCHLORIDE, METHADONE, |
||||
| 1011 | 24934079 |
CA |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, LEVOTHYROXINE SODIUM, HYDROXYZINE, LOSARTAN, AMLODIPINE, |
||||
| 1012 | 24934083 |
TH |
70 | 2 |
Malignant neoplasm progression, Off label use, |
||||
CABOZANTINIB, |
||||
| 1013 | 24934089 |
US |
62 | 1 |
Malignant neoplasm progression, Metastatic renal cell carcinoma, Weight decreased, Drug ineffective, |
||||
CABOZANTINIB, NIVOLUMAB, |
||||
| 1014 | 24934091 |
US |
42 | 2 |
Malignant neoplasm progression, Asthenia, Nausea, Pain, Off label use, |
||||
CABOZANTINIB, |
||||
| 1015 | 24934092 |
US |
2 | |
Malignant neoplasm progression, Off label use, |
||||
CABOZANTINIB, |
||||
| 1016 | 24934095 |
CA |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, PANTOPRAZOLE, BLACK COHOSH, BRYONIA ALBA WHOLE, TOXICODENDRON PUBESCENS WHOLE, ARNICA MONTANA, CAUSTICUM, FERROSOFERRIC PHOSPHATE, SODIUM SULFATE ANHYDROUS, STRYCHNOS NUX-VOMICA SEED, RHODODENDRON AUREUM WHOLE, CITRULLUS COLOCYNTHIS WHOLE, SOLANUM DULCAMARA WHOLE, KALMIA LATIFOLIA WHOLE, MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE, ARSENIC TRIOXIDE, AND TRIBASIC CALCIUM PHOSPHATE, BERBERIS VULGARIS ROOT BARK, BRYONIA ALBA ROOT, PHENOL, MILK THISTLE, CHELIDONIUM MAJUS, JUNIPER BERRY, LYCOPODIUM CLAVATUM SPORE, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE, SODIUM SULFATE, STRYCHNOS NUX-VOMICA SEED, PHOSPHORUS, LACTIC ACID, L-, TARAXACUM OFFICINALE, VISCUM ALBUM FRUITING TOP, AND YUCCA FILAMENTOSA, ARTEMISIA CINA PRE-FLOWERING TOP, TANACETUM VULGARE WHOLE, ARTEMISIA VULGARIS WHOLE, DRYOPTERIS FILIX-MAS ROOT, MERCURIC CHLORIDE, AND GRAPHITE, AMBROSIA ARTEMISIAEFOLIA, ARALIA RACEMOSA, ARNICA MONTANA, CALENDULA OFFICINALIS, CHROMICUM ACIDUM, ECHINACEA PURPUREA, EUCALYPTOL, KALI BICHROMICUM, KALI MURIATICUM, KALI SULPHURICUM, LAC VACCINUM, MERCURIUS IODATUS FLAVUS, MERCURIUS SULPHURATUS RUBER, NATRUM ARSENICICUM, ROSA DAMASCENA, SABADILLA, SANGUINARINUM NITRICUM, SYMPHYTUM OFFICINALE, NAJA NAJA WHOLE, SCROPHULARIA NODOSA, LACTIC ACID, DL-, AND RADIUM BROMIDE, APIS MELLIFERA, ASPARAGUS, BERBERIS VULGARIS ROOT BARK, LYTTA VESICATORIA, CHELIDONIUM MAJUS, JUNIPER BERRY, MAGNESIUM CHLORIDE, SODIUM CHLORIDE, POPULUS TREMULOIDES BARK, RHUS AROMATICA ROOT BARK, RUBIA TINCTORUM ROOT, SAW PALMETTO, SOLIDAGO VIRGAUREA FLOWERING TOP, TARAXACUM OFFICINALE, AND ARCTOSTAPHYLOS UVA-URSI LEAF, AVENA SATIVA WHOLE, VALERIANA OFFICINALIS WHOLE, HUMULUS LUPULUS WHOLE, ARABICA COFFEE BEAN, STRYCHNOS IGNATII WHOLE, ZINC VALERATE DIHYDRATE, AMMONIUM BROMIDE, CHAMOMILE, ESCHSCHOLZIA CALIFORNICA, AND PASSIFLORA INCARNATA WHOLE, APIS MELLIFICA, ARGENTUM NITRICUM, BADIAGA, BELLADONNA, CANTHARIS, CAUSTICUM, CHIMAPHILA UMBELLATA, COLOCYNTHIS, CUBEBA OFFICINALIS, CUCURBITA CITRULLUS, CUCURBITA PEPO FLOWER, ECHINACEA ANGUSTIFOLIA, EQUISETUM HYEMALE, ERYNGIUM AQUATICUM, FERRUM PHOSPHORICUM, MITCHELLA REPENS, OLEUM SANTALI, PETROSELINUM SATIVUM, PIPER METHYSTICUM, POPULUS TREMULOIDES BARK, SARSAPARILLA, TEREBINTHINA, UVA URSI, ACHILLEA MILLEFOLIUM, ARNICA MONTANA, HYPERICUM PERFORATUM, HORSE CHESTNUT, AND VISCUM ALBUM WHOLE, ACONITUM NAPELLUS, AMERICAN GINSENG, ARSENICUM IODATUM, BLATTA ORIENTALIS, CALCAREA SULPHURICA, CARPINUS BETULUS FLOWER, CUPRUM METALLICUM, GRINDELIA, HEPAR SULPHURIS CALCAREUM, IPECACUANHA, JUSTICIA ADHATODA, KALI IODATUM, LOBELIA INFLATA, NAPHTHALINUM, NARCISSUS PSEUDONARCISSUS, PINE TAR, POPULUS CANDICANS, TABACUM, THUJA OCCIDENTALIS, THYMUS SERPYLLUM, PASSIFLORA INCARNATA WHOLE, SMILAX ORNATA WHOLE, PHYTOLACCA AMERICANA ROOT, STILLINGIA SYLVATICA ROOT, TRIFOLIUM PRATENSE WHOLE, ARCTIUM LAPPA WHOLE, PRUNUS DULCIS WHOLE, FRANGULA PURSHIANA BARK, BERBERIS VULGARIS WHOLE, GLYCYRRHIZA GLABRA WHOLE, AND LARREA DIVARICATA WHOLE, ALOE, ACTIVATED CHARCOAL, COLCHICUM AUTUMNALE BULB, COLLINSONIA CANADENSIS ROOT, CUCURBITA PEPO FLOWER, DRYOPTERIS FILIX-MAS ROOT, INDOLE, SKIM MILK, LYCOPODIUM CLAVATUM SPORE, ACHILLEA MILLEFOLIUM, SODIUM SULFATE, FRANGULA PURSHIANA BARK, SCROPHULARIA NODOSA, SKATOLE, TARAXACUM OFFICINALE, TARTARIC ACID, ARANEUS DIADEMATUS, ARISAEMA TRIPHYLLUM ROOT, ASTERIAS RUBENS, BAPTISIA TINCTORIA, BARIUM IODIDE, ECHINACEA ANGUSTIFOLIA, FERROUS IODIDE, GOLDENSEAL, LACHESIS MUTA VENOM, PHYTOLACCA AMERICANA ROOT, PINUS SYLVESTRIS FLOWERING TOP, SCROPHULARIA NODOSA, SPONGIA OFFICINALIS SKELETON, ROASTED, AND TEUCRIUM SCORODONIA FLOWERING TOP, ALFALFA, ALLIUM SATIVUM, ASPARAGUS OFFICINALIS, AVENA SATIVA, BELLADONNA, BERBERIS VULGARIS, CHELIDONIUM MAJUS, GLYCYRRHIZA GLABRA, HYDRASTIS CANADENSIS, JUNIPERUS VIRGINIANA, NICCOLUM METALLICUM, PASSIFLORA INCARNATA, SARCOLACTICUM ACIDUM, SOLIDAGO VIRGAUREA, TARAXACUM OFFICINALE, ALNUS GLUTINOSA, APIS MELLIFICA, BERBERIS VULGARIS, CALCIUM SULFIDE, CROTON TIGLIUM, ECHINACEA ANGUSTIFOLIA, GRAPHITE, GRINDELIA HIRSUTULA, HYDROFLUORIC ACID, JUGLANS REGIA, LYCOPODIUM CLAVATUM, MERCURIUS SOLUBILIS, MYRISTICA SEBIFERA, NITRICUM ACIDUM, PHOSPHORUS, RHUS TOXICODENDRON, SCROPHULARIA NODOSA, SOLIDAGO VIRGAUREA, SULPHUR, VINCA MINOR, ATENOLOL, PREDNISONE, LEVOTHYROXINE SODIUM, SULFAMETHOXAZOLE AND TRIMETHOPRIM, EPINEPHRINE, SODIUM PHOSPHATE, HYDROCORTISONE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 1017 | 24934096 |
CA |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, PANCRELIPASE, LEVOTHYROXINE SODIUM, PYRIDOXINE HYDROCHLORIDE, CALCIUM, ERGOCALCIFEROL, AMLODIPINE, ALLOPURINOL, PANTOPRAZOLE, PREDNISONE, AXITINIB, |
||||
| 1018 | 24934098 |
US |
2 | |
Malignant neoplasm progression, Rash pruritic, Diarrhoea, Fatigue, Dehydration, Thirst, Dry mouth, |
||||
CABOZANTINIB, LENVATINIB, LENVATINIB, PEMBROLIZUMAB, PEMBROLIZUMAB, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, AMLODIPINE, AZELASTINE, CALCIUM, CETIRIZINE HCL, CETIRIZINE, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, FAMOTIDINE, LEVOTHYROXINE, LEVOTHYROXINE SODIUM, |
||||
| 1019 | 24934103 |
CA |
2 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, LEVOTHYROXINE SODIUM, LOVASTATIN, LEVETIRACETAM, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM IN SODIUM CHLORIDE, ENOXAPARIN SODIUM, |
||||
| 1020 | 24934109 |
US |
1 | |
Malignant neoplasm progression, Fatigue, Product dose omission issue, |
||||
CABOZANTINIB, CABOZANTINIB, |
||||
| 1021 | 24934110 |
CA |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, NIFEDIPINE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, LEVOTHYROXINE SODIUM, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, |
||||
| 1022 | 24934118 |
TW |
72 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1023 | 24934124 |
US |
77 | 1 |
Ascites, Malignant neoplasm progression, Liver function test increased, Weight decreased, Abdominal pain upper, Constipation, Diarrhoea, Decreased appetite, Abdominal distension, Product prescribing issue, Inappropriate schedule of product administration, |
||||
CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, |
||||
| 1024 | 24934128 |
CA |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, CABOZANTINIB, PREGABALIN, INDAPAMIDE, CALCIUM, PRIMIDONE, PRIMIDONE, AMLODIPINE, DULOXETINE HYDROCHLORIDE, DULOXETINE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM, DOXAZOSIN, DOXAZOSIN MESYLATE, APIXABAN, POLYETHYLENE GLYCOL (3350), POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 400, ALBUTEROL SULFATE, ALBUTEROL, ZOLEDRONIC ACID, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 1025 | 24934507 |
GB |
21 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1026 | 24934513 |
TH |
63 | 2 |
Malignant neoplasm progression, Diarrhoea, |
||||
CABOZANTINIB, |
||||
| 1027 | 24934519 |
US |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, CABOZANTINIB, |
||||
| 1028 | 24934520 |
US |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1029 | 24934523 |
US |
2 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1030 | 24934527 |
US |
1 | |
Malignant neoplasm progression, Skin discolouration, Rash macular, Pain in extremity, |
||||
CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, LENVATINIB, |
||||
| 1031 | 24934528 |
US |
33 | 2 |
Malignant neoplasm progression, Taste disorder, Diarrhoea, Fatigue, Nausea, Decreased appetite, Oral pain, Dry skin, Pain in extremity, Weight decreased, Haemoglobin increased, Off label use, |
||||
CABOZANTINIB, ALBUTEROL SULFATE, ALBUTEROL, BENZONATATE, VENLAFAXINE HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE, LAMOTRIGINE, ARIPIPRAZOLE, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, |
||||
| 1032 | 24934529 |
TH |
74 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1033 | 24934531 |
DE |
73 | 1 |
Malignant neoplasm progression, Asthenia, |
||||
CABOZANTINIB, NIVOLUMAB, |
||||
| 1034 | 24934534 |
CA |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, POLYETHYLENE GLYCOL 3350, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, CALCIUM, HYDROCHLOROTHIAZIDE, AMLODIPINE, STANDARDIZED SENNA CONCENTRATE, PREGABALIN, FESOTERODINE FUMARATE, DULOXETINE HYDROCHLORIDE, DULOXETINE, |
||||
| 1035 | 24934536 |
DE |
51 | 1 |
Malignant neoplasm progression, Therapy non-responder, |
||||
CABOZANTINIB, CANDESARTAN, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, |
||||
| 1036 | 24934547 |
CZ |
2 | |
Malignant neoplasm progression, Diarrhoea, |
||||
CABOZANTINIB, CABOZANTINIB, |
||||
| 1037 | 24934589 |
GB |
1 | |
Death, Malignant neoplasm progression, Drug ineffective for unapproved indication, |
||||
AZACITIDINE, AZACITIDINE FOR, VENETOCLAX, |
||||
| 1038 | 24934590 |
GB |
2 | |
Death, Malignant neoplasm progression, Drug ineffective, |
||||
AZACITIDINE, AZACITIDINE FOR, VENETOCLAX, |
||||
| 1039 | 24934592 |
GB |
2 | |
Death, Malignant neoplasm progression, Drug ineffective, |
||||
AZACITIDINE, AZACITIDINE FOR, VENETOCLAX, VENETOCLAX, CYTARABINE, CYTARABINE, |
||||
| 1040 | 24934820 |
GB |
2 | |
Drug ineffective, Malignant neoplasm progression, |
||||
AZACITIDINE, AZACITIDINE FOR, VENETOCLAX, |
||||
| 1041 | 24934821 |
GB |
1 | |
Death, Malignant neoplasm progression, Drug ineffective, |
||||
AZACITIDINE, AZACITIDINE FOR, VENETOCLAX, CYTARABINE, |
||||
| 1042 | 24934858 |
GB |
1 | |
Death, Malignant neoplasm progression, Drug ineffective, |
||||
AZACITIDINE, AZACITIDINE FOR, VENETOCLAX, CYTARABINE, |
||||
| 1043 | 24935120 |
GB |
1 | |
Death, Malignant neoplasm progression, Drug ineffective, |
||||
AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, VENETOCLAX, VENETOCLAX, |
||||
| 1044 | 24935171 |
DE |
2 | |
Malignant neoplasm progression, Infection, |
||||
PEMETREXED, PEMETREXED DISODIUM, CISPLATIN, PEMBROLIZUMAB, |
||||
| 1045 | 24935173 |
RU |
||
Pneumonitis, Metastases to central nervous system, Malignant neoplasm progression, |
||||
DURVALUMAB, |
||||
| 1046 | 24935443 |
GB |
2 | |
Death, Malignant neoplasm progression, Drug ineffective, |
||||
AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, VENETOCLAX, VENETOCLAX, VENETOCLAX, |
||||
| 1047 | 24935584 |
US |
2 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1048 | 24935585 |
US |
71 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1049 | 24935593 |
US |
1 | |
Malignant neoplasm progression, Blood pressure increased, Back pain, Constipation, Decreased appetite, Chest pain, Lung disorder, Dry mouth, Off label use, |
||||
CABOZANTINIB, CABOZANTINIB, FINASTERIDE, TERAZOSIN, TERAZOSIN HYDROCHLORIDE, |
||||
| 1050 | 24935594 |
CA |
50 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, LABETALOL, AMLODIPINE BESYLATE, SIROLIMUS, MYCOPHENOLIC ACID, AXITINIB, PREDNISONE, CLOZAPINE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 1051 | 24935596 |
CA |
40 | 2 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1052 | 24935599 |
GB |
51 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, NIVOLUMAB, DENOSUMAB, |
||||
| 1053 | 24935603 |
TW |
53 | 1 |
Malignant neoplasm progression, Palmar-plantar erythrodysaesthesia syndrome, |
||||
CABOZANTINIB, |
||||
| 1054 | 24935604 |
CO |
45 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1055 | 24935608 |
US |
1 | |
Malignant neoplasm progression, Cellulitis, |
||||
CABOZANTINIB, CABOZANTINIB, FAMOTIDINE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, |
||||
| 1056 | 24935609 |
US |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1057 | 24935619 |
US |
2 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1058 | 24935620 |
US |
1 | |
Malignant neoplasm progression, Fatigue, Off label use, |
||||
CABOZANTINIB, CABOZANTINIB, |
||||
| 1059 | 24935637 |
CO |
66 | 2 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1060 | 24935644 |
US |
1 | |
Malignant neoplasm progression, Diarrhoea, Pain in jaw, Muscular weakness, Emotional distress, Off label use, |
||||
CABOZANTINIB, DIVALPROEX SODIUM, GABAPENTIN, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, LEVETIRACETAM, ALBUTEROL SULFATE, ALBUTEROL, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, OXYCODONE, IVOSIDENIB, LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 1061 | 24935646 |
US |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1062 | 24935650 |
CO |
45 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1063 | 24935651 |
CA |
2 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, AMLODIPINE, LEVOTHYROXINE SODIUM, LABETALOL, APIXABAN, ERGOCALCIFEROL, LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE, |
||||
| 1064 | 24935652 |
CO |
38 | 1 |
Malignant neoplasm progression, Drug ineffective, |
||||
CABOZANTINIB, |
||||
| 1065 | 24935658 |
US |
2 | |
Thrombosis, Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1066 | 24935662 |
US |
1 | |
Malignant neoplasm progression, Drug ineffective, |
||||
CABOZANTINIB, |
||||
| 1067 | 24935668 |
CA |
2 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, PANTOPRAZOLE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 1068 | 24935669 |
US |
1 | |
Malignant neoplasm progression, Madarosis, Throat tightness, Oropharyngeal pain, Alopecia, Hair colour changes, Dysphagia, Diarrhoea, Oral pain, Tongue discomfort, Mastication disorder, Cancer pain, |
||||
CABOZANTINIB, ARIPIPRAZOLE, GABAPENTIN, LEVOTHYROXINE SODIUM, VENLAFAXINE HYDROCHLORIDE, |
||||
| 1069 | 24935676 |
BR |
83 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, NIVOLUMAB, |
||||
| 1070 | 24935677 |
CA |
66 | 1 |
Malignant neoplasm progression, Palmar-plantar erythrodysaesthesia syndrome, |
||||
CABOZANTINIB, CABOZANTINIB, NIVOLUMAB, |
||||
| 1071 | 24935681 |
US |
2 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, NIVOLUMAB, ERGOCALCIFEROL, POLYETHYLENE GLYCOL 3350, ONDANSETRON HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, AMLODIPINE BESYLATE, LABETALOL HYDROCHLORIDE, LABETALOL, MIRTAZAPINE, LORAZEPAM, |
||||
| 1072 | 24935689 |
CO |
65 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1073 | 24935690 |
AU |
48 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, APIXABAN, OXYCODONE, OXYCODONE, |
||||
| 1074 | 24935691 |
CO |
70 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1075 | 24935693 |
US |
1 | |
Malignant neoplasm progression, Prescribed overdose, Off label use, |
||||
CABOZANTINIB, TEMOZOLOMIDE, |
||||
| 1076 | 24935699 |
CO |
51 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1077 | 24935710 |
US |
1 | |
Malignant neoplasm progression, Oncologic complication, |
||||
CABOZANTINIB, CABOZANTINIB, FINGOLIMOD HCL, FINGOLIMOD, FINGOLIMOD HYDROCHLORIDE, LOSARTAN POTASSIUM, LOSARTAN, |
||||
| 1078 | 24935717 |
US |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1079 | 24935720 |
US |
2 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1080 | 24935721 |
CA |
2 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, METHADONE, |
||||
| 1081 | 24935724 |
US |
2 | |
Malignant neoplasm progression, Decreased appetite, Nausea, |
||||
CABOZANTINIB, CABOZANTINIB, |
||||
| 1082 | 24935739 |
US |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1083 | 24935742 |
CA |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, APIXABAN, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, |
||||
| 1084 | 24935755 |
US |
2 | |
Metastatic renal cell carcinoma, Malignant neoplasm progression, Fatigue, |
||||
CABOZANTINIB, GABAPENTIN, ATORVASTATIN CALCIUM, CLOPIDOGREL, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, OXYCODONE HYDROCHLORIDE, OXYCODONE, LIDOCAINE, LIDOCAINE HYDROCHLORIDE, BURN RELIEF, MAXIMUM STRENGTH PAIN RELIEVER, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, LIDOCAINE 4%, LIDOCAINE, MENTHOL, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, PEMBROLIZUMAB, |
||||
| 1085 | 24935758 |
US |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, CABOZANTINIB, IRBESARTAN, ROSUVASTATIN, |
||||
| 1086 | 24935777 |
CA |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, NAPROXEN, NAPROXEN SODIUM, LEVETIRACETAM, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM IN SODIUM CHLORIDE, BISOPROLOL FUMARATE, LEVOTHYROXINE SODIUM, AMLODIPINE, DUTASTERIDE, QUETIAPINE, QUETIAPINE EXTENDED-RELEASE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, DOCUSATE SODIUM, DOCUSATE SODIUM - SENNOSIDES, |
||||
| 1087 | 24935784 |
US |
1 | |
Malignant neoplasm progression, Drug ineffective, |
||||
CABOZANTINIB, CABOZANTINIB, |
||||
| 1088 | 24935787 |
US |
49 | 2 |
Malignant neoplasm progression, Neoplasm, Drug ineffective, Inappropriate schedule of product administration, |
||||
CABOZANTINIB, |
||||
| 1089 | 24935795 |
BR |
70 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, NIVOLUMAB, ROSUVASTATIN, CYANOCOBALAMIN, |
||||
| 1090 | 24935800 |
JP |
56 | 1 |
Malignant neoplasm progression, Therapy partial responder, |
||||
CABOZANTINIB, |
||||
| 1091 | 24935804 |
US |
2 | |
Blood sodium decreased, Malignant neoplasm progression, |
||||
CABOZANTINIB, CABOZANTINIB, VITAMIN E, CREAM, ERGOCALCIFEROL, THIAMINE HYDROCHLORIDE, RIBOFLAVIN 5 PHOSPHATE SODIUM, DEXPANTHENOL AND NIACINAMIDE, ONDANSETRON HYDROCHLORIDE, CALCITRIOL, CALCITRIOL CAPSULES 0.25 MCG, CALCITRIOL CAPSULES 0.5 MCG, LEVOTHYROXINE SODIUM, SPIRONOLACTONE, OLMESARTAN MEDOXOMIL, |
||||
| 1092 | 24935805 |
US |
51 | 2 |
Malignant neoplasm progression, Dysphonia, Diarrhoea, Fatigue, Oral mucosal blistering, Hyperkeratosis, Weight decreased, Decreased appetite, Acne, Muscle spasms, Dry skin, Ageusia, Chills, Cancer pain, Oncologic complication, Dyspnoea, |
||||
CABOZANTINIB, CABOZANTINIB, LEVOTHYROXINE, GABAPENTIN, SERTRALINE, METHOCARBAMOL, METHOCARBAMOL TABLETS, |
||||
| 1093 | 24935816 |
US |
60 | 2 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, CABOZANTINIB, |
||||
| 1094 | 24935820 |
US |
1 | |
Malignant neoplasm progression, Drug ineffective, Off label use, |
||||
CABOZANTINIB, |
||||
| 1095 | 24935822 |
US |
1 | |
Dehydration, Blood sodium abnormal, Malignant mesenteric neoplasm, Infusion, Malignant neoplasm progression, Gait inability, Respiratory tract irritation, Neoplasm prostate, Product storage error, Product size issue, |
||||
CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, NIVOLUMAB, NIVOLUMAB, |
||||
| 1096 | 24935825 |
US |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
| 1097 | 24935827 |
US |
1 | |
Malignant neoplasm progression, Illness, Pain, |
||||
CABOZANTINIB, |
||||
| 1098 | 24935848 |
US |
1 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, CABOZANTINIB, IRON SUCROSE, |
||||
| 1099 | 24935850 |
US |
2 | |
Malignant neoplasm progression, |
||||
CABOZANTINIB, CITALOPRAM, CITALOPRAM HYDROBROMIDE, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, LEVOTHYROXINE, DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, PROCHLORPERAZINE, ALPRAZOLAM, |
||||
| 1100 | 24935853 |
TW |
83 | 1 |
Malignant neoplasm progression, |
||||
CABOZANTINIB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28